A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B. Academic Article uri icon

Overview

MeSH

  • Adult
  • Aged
  • Female
  • Humans
  • Immunotherapy
  • Killer Cells, Lymphokine-Activated
  • Killer Cells, Natural
  • Male
  • Middle Aged
  • Recombinant Proteins

MeSH Major

  • Interferon-beta
  • Interleukin-2
  • Lymphoma, Non-Hodgkin

abstract

  • Interleukin-2 (IL-2) and interferon-beta (IFN-beta) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-beta is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-beta in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-beta is not effective therapy for NHL in the doses and schedule used in this study.

publication date

  • August 1992

has subject area

  • Adult
  • Aged
  • Female
  • Humans
  • Immunotherapy
  • Interferon-beta
  • Interleukin-2
  • Killer Cells, Lymphokine-Activated
  • Killer Cells, Natural
  • Lymphoma, Non-Hodgkin
  • Male
  • Middle Aged
  • Recombinant Proteins

Research

keywords

  • Clinical Trial
  • Journal Article
  • Randomized Controlled Trial

Identity

Language

  • eng

PubMed ID

  • 1504052

Additional Document Info

start page

  • 115

end page

  • 122

volume

  • 12

number

  • 2